RecruitingPhase 1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

United States24 participantsStarted 2023-10-26

Plain-language summary

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Follicular Lymphoma (FL) grade 1, grade 2, or grade 3a
✓. Marginal Zone Lymphoma (MZL) nodal of extranodal:
✓. Diffuse large B-cell lymphoma (DLBCL), including transformed follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL) and grade 3b Follicular Lymphoma (FL).
✓. R/R disease after 2 or more prior lines of therapy OR
✓. Relapsed following autologous SCT, OR
✓. Ineligible for autologous SCT.
✓. Mantle cell lymphoma
✓. R/R disease as defined by disease progression after last regimen (including autologous SCT) OR

What they're measuring

Incidence of adverse events (AEs)

Timeframe: From Day 0 to 2 years post-treatment

Incidence of Dose Limiting Toxicity (DLT)

Timeframe: From Day 0 to 2 years post-treatment

Trial details

NCT IDNCT06026319

SponsorMarcela V. Maus, M.D.,Ph.D.

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01-01

Contact for this trial

Matthew Frigault, MD

(617) 643-6175 MFRIGAULT@partners.org

View on ClinicalTrials.gov More Non-hodgkin Lymphoma trials